Literature DB >> 15153563

Increased infarct size in uremic rats: reduced ischemia tolerance?

Ralf Dikow1, Lars Philipp Kihm, Martin Zeier, Jolanthe Kapitza, Johannes Törnig, Kerstin Amann, Christiane Tiefenbacher, Eberhard Ritz.   

Abstract

In patients with renal failure, myocardial infarction (MI) is more frequent and the rate of death from acute MI is very high. It has been argued that ischemia tolerance of the heart is reduced in uremia, but direct evidence for this hypothesis has not been provided. It was the purpose of this study (1) to ligate the left coronary artery and to measure the nonperfused area (risk area: total infarction plus penumbra) as well as the area of total infarction in subtotally nephrectomized (SNX) rats compared with sham-operated pair-fed control rats and (2) to examine the effects of potential confounders such as BP, sympathetic overactivity, and salt retention. The left coronary artery was ligated for 60 min, followed by reperfusion for 90 min. For visualizing perfused myocardium, lissamine green ink was injected. The nonperfused area (lissamine exclusion) and the area of total infarction (triphenyltetrazolium chloride stain) were assessed in sections of the left ventricle using image analysis. Groups of SNX rats also received: antihypertensive treatment (nadolol plus hydralazine); moxonidine; high salt diet or low salt diet (1.58% versus 0.015%). In surviving animals, the nonperfused area at risk (as the proportion of total left ventricular area), presumably determined by the geometry of vascular supply, was similar in sham-operated and SNX animals (0.38 +/- 0.13 versus 0.45 +/- 0.09; NS). In contrast, the infarcted area, given as a proportion of the nonperfused risk area, was significantly (P < 0.003) higher in SNX (0.68 +/- 0.09) compared with sham-operated (0.51 +/- 0.11) rats and was not altered by any of the above interventions. The finding that a greater proportion of nonperfused myocardium undergoes total necrosis is consistent with the hypothesis of reduced ischemia tolerance of the heart in renal failure. The findings could explain the high rate of death from MI in patients with impaired renal function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15153563     DOI: 10.1097/01.asn.0000130154.42061.c6

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  24 in total

1.  Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis.

Authors:  Lars P Kihm; Sandra Müller-Krebs; Julia Klein; Gregory Ehrlich; Laura Mertes; Marie-Luise Gross; Antonysunil Adaikalakoteswari; Paul J Thornalley; Hans-Peter Hammes; Peter P Nawroth; Martin Zeier; Vedat Schwenger
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

2.  Mitochondrial dysfunction in uremic cardiomyopathy.

Authors:  David Taylor; Sunil Bhandari; Anne-Marie L Seymour
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-13

3.  The effect of uraemia on the duration of arrhythmias in the context of cardioprotective ischaemic conditioning strategies.

Authors:  Kieran McCafferty; Conor J Byrne; Julius Kieswich; Martin Raftery; Christoph Thiemermann; Muhammad M Yaqoob
Journal:  Heart Asia       Date:  2014-05-24

4.  IκB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD.

Authors:  Jianmin Chen; Julius E Kieswich; Fausto Chiazza; Amie J Moyes; Thomas Gobbetti; Gareth S D Purvis; Daniela C F Salvatori; Nimesh S A Patel; Mauro Perretti; Adrian J Hobbs; Massimo Collino; Muhammad M Yaqoob; Christoph Thiemermann
Journal:  J Am Soc Nephrol       Date:  2016-05-06       Impact factor: 10.121

5.  Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.

Authors:  Vera Krane; Mario Berger; Jürgen Lilienthal; Karl Winkler; Christian Schambeck; Christoph Wanner
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

6.  Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage.

Authors:  David M Charytan; Hicham Skali; Nishant R Shah; Vikas Veeranna; Michael K Cheezum; Viviany R Taqueti; Takashi Kato; Courtney R Bibbo; Jon Hainer; Sharmila Dorbala; Ron Blankstein; Marcelo F Di Carli
Journal:  Kidney Int       Date:  2017-10-13       Impact factor: 10.612

Review 7.  Use of nicorandil in cardiovascular disease and its optimization.

Authors:  Shigeo Horinaka
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

8.  [Cardiorenal syndrome: limits of heart failure therapy].

Authors:  L Großekettler; B Schmack; V Schwenger
Journal:  Herz       Date:  2013-09       Impact factor: 1.443

Review 9.  Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.

Authors:  David Charytan
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

10.  The growth factor midkine regulates the renin-angiotensin system in mice.

Authors:  Akinori Hobo; Yukio Yuzawa; Tomoki Kosugi; Noritoshi Kato; Naoto Asai; Waichi Sato; Shoichi Maruyama; Yasuhiko Ito; Hiroyuki Kobori; Shinya Ikematsu; Akira Nishiyama; Seiichi Matsuo; Kenji Kadomatsu
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.